MicroRNA-193b Enhances Tumor Progression via Down Regulation of Neurofibromin 1

Michelle Lenarduzzi1,2, Angela B. Y. Hui1, Nehad M. Alajez3, Wei Shi1, Justin Williams1, Shijun Yue1, Brian O’Sullivan4,5, Fei-Fei Liu1,2,4,5*

1 Ontario Cancer Institute, University Health Network, Toronto, Canada, 2 Department of Medical Biophysics, University of Toronto, Toronto, Canada, 3 Stem Cell Unit, Department of Anatomy, College of Medicine, King Saud University, Riyadh, Saudi Arabia, 4 Radiation Medicine Program University Health Network, Toronto, Canada, 5 Department of Radiation Oncology, University of Toronto, Toronto, Ontario

Abstract

Despite improvements in therapeutic approaches for head and neck squamous cell carcinomas (HNSCC), clinical outcome has remained disappointing, with 5-year overall survival rates hovering around 40–50%, underscoring an urgent need to better understand the biological bases of this disease. We chose to address this challenge by studying the role of micro-RNAs (miRNAs) in HNSCC. MiR-193b was identified as an over-expressed miRNA from global miRNA profiling studies previously conducted in our lab, and confirmed in HNSCC cell lines. In vitro knockdown of miR-193b in FaDu cancer cells substantially reduced cell proliferation, migration and invasion, along with suppressed tumour formation in vivo. By integrating in silico prediction algorithms with in vitro experimental mRNA profilings, plus mRNA expression data of clinical specimens, neurofibromin 1 (NF1) was identified to be a target of miR-193b. Concomitantly, miR-193b knockdown decreased NF1 transcript and protein levels significantly. Luciferase reporter assays confirmed the direct interaction of miR-193b with NF1. Moreover, p-ERK, a downstream target of NF1 was also suppressed after miR-193b knockdown. FaDu cells treated with a p-ERK inhibitor (U0126) phenocopied the reduced cell proliferation, migration and invasion observed with miR-193b knockdown. Finally, HNSCC patients whose tumours expressed high levels of miR-193b experienced a lower disease-free survival compared to patients with low miR-193b expression. Our findings identified miR-193b as a potentially novel prognostic marker in HNSCC that drives tumour progression via down-regulating NF1, in turn leading to activation of ERK, resulting in proliferation, migration, invasion, and tumour formation.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide, with ~650,000 new cases diagnosed, and ~350,000 deaths annually [1,2]. With the majority of patients presenting with locally advanced disease, and despite improvements in treatment approaches, the 5-year survival rates of 40–50% have not significantly improved in the past decades [3], underscoring an urgent need to better understand the molecular mechanisms underlying the biology of this disease.

We have chosen to address HNSCC biology through the lens of micro-RNAs (miRNAs), an endogenous class of non-coding RNAs that negatively regulate gene expression through translational repression or degradation of mRNAs targets in a sequence specific manner [4]. Since their initial identification in nematodes in 1995, miRNAs have been described to regulate a number of biological processes, including cancer [5,6]. In silico algorithms predict that miRNAs control one third of protein encoding genes, rendering them as one of the largest classes of gene regulators [7]. In recent years, aberrant miRNA expression has been recognized to enhance cancer progression via their mRNA targets [8,9]. In this study, we report the over-expression of miR-193b in HNSCC, based on our global miRNA profiling of HNSCC cell lines, our comprehensive miRNA profiling study of relapsed vs. non-relapsed primary HNSCC tissues [10], and a study by Avissar et al. [11]. In turn, we have identified neurofibromin 1 (NF1) as a target of miR-193b, which drives HNSCC progression via ERK activation.

Materials and Methods

Ethics Statement

All animal experiments were conducted in accordance to guidelines of the Animal Care Committee at the University Health Network (Toronto, Canada). The protocol was approved by the Animal Care Committee at the University Health Network (Protocol Number: 342.19).

Patient samples were collected from a phase III randomized study (331 participants) of hyperfractionated radiotherapy conducted in 1988 to 1995 [10,12], with approval from the University Health Network Institutional Research Ethics Board (REB approval # 07-0521-CE). Written or Oral consent could not be obtained from the patients due to the period of our cohort (1988–
The human hypopharyngeal HNSCC FaDu cell line was obtained from the American Type Culture Collection (Manassas, VA), and cultured according to the manufacturer’s specifications. The human laryngeal squamous cell lines, UTSCC-8 and UTSCC-42a (kind gifts from R Grénman, Turku University Hospital, Turku, Finland) [13,14] were maintained with DMEM supplemented with 10% fetal bovine serum (Wisent, Inc) and 100 mg/L penicillin/streptomycin. The normal oral epithelial cells (NOEs) were purchased commercially and cultured in the recommended medium (Celprogen). All cells were maintained in a 37°C incubator with humidified 5% CO₂, authenticated at the Centre for Applied Genomics (Hospital for Sick Children, Toronto, Canada) according to specifications. MicroRNA profiles of three HNSCC cell lines (FaDu, UTSCC-42a and UTSCC-8) compared Canada) according to specifications. MicroRNA profiles of three

The viability of FaDu cells transfected with LNA-scrambled or LNA-193b, FaDu cells were transfected with LNA-scrambled or LNA-193b, UTSCC-42a (kind gifts from R Grénman, Turku University Hospital, Turku, Finland) [13,14] were maintained with DMEM supplemented with 10% fetal bovine serum (Wisent, Inc) and 100 mg/L penicillin/streptomycin. The normal oral epithelial cells (NOEs) were purchased commercially and cultured in the recommended medium (Celprogen). All cells were maintained in a 37°C incubator with humidified 5% CO₂, authenticated at the Centre for Applied Genomics (Hospital for Sick Children, Toronto, Canada) according to specifications. MicroRNA profiles of three HNSCC cell lines (FaDu, UTSCC-42a and UTSCC-8) compared Canada) according to specifications. MicroRNA profiles of three HNSCC cell lines (FaDu, UTSCC-42a and UTSCC-8) compared

The viability of FaDu cells transfected with locked nucleic acid (LNA) probe containing a sequence specific antisense oligonucleotide targeting miR-193b, miRCURY LNA™ microRNA 193b Power inhibitor (Exiqon). A scrambled miRNA sequence, miRCURY LNA™ microRNA Power inhibitors Control A served as a negative control.

Viability and Clonogenic Assays

The viability of FaDu cells transfected with LNA-193b transfection, as previously described [15]. Briefly, cells were re-seeded in FACS buffer containing RNase A (Sigma, St. Louis, MO, USA) and propidium iodine. Cells were incubated in the dark at room temperature before being analyzed in BD FACScalibur (Becton Dickinson, San Jose, CA, USA) using FL-2A and FL-2W channels. The flow cytometry data were analyzed using FlowJo 7.5 software (Tree Star, San Carlos, CA, USA).

Cell Migration and Invasion

To assess the migration and invasion potential of FaDu cells after transfection with LNA-193b, BD BioCoat Control 8.0 um PET Membranes, were utilized to measure migration, and BD BioCoat Matrigel™ invasion chambers with a uniform layer of BD Matrigel basement membrane matrix were used to measure invasion. For both the migration and invasion assays, the chambers were placed in a 24-well plate, and 1.5×10⁵ cells in 0.5% serum were plated to the top of the chamber, and 20% serum added to the bottom chamber. Twenty-four hours later, inserts were fixed and stained with SIEMENNS DIFF-QUICK stain set (Siemens Healthcare Diagnostics), and the number of migrating and invading cells was counted using a light microscope.

Luciferase Assay

The 3’ UTR of NF1 containing the predicted miR-193b binding site was amplified using AmpliTaq gold DNA polymerase (Applied Biosystems), using the indicated primers (Table S1B). Next, the PCR product was purified, digested with SpeI and HindIII, then cloned downstream of the firefly luciferase gene in the pMIR-REPORT vector (Ambion, Inc.). Another vector was constructed which carried a mutation of the NF1 3’UTR in the seed region of the miR-193b binding site using the indicated primers (Table S1B). Twenty-four hours before transfection, FaDu cells were seeded in 24-well plates. Cells were then transfected with 40 nM of LNA-scrambled or LNA-193b, and 4–6 hours later, cells were re-transfected with 100 ng of pMIR-REPORT or pMIR-REPORT NF1-UTR, along with 50 ng of pRL-SV40 vector (Promega Biosciences) carrying the Renilla luciferase gene. At 24–72 h after transfection, luciferase activity was measured using the Dual-Glo luciferase assay system (Promega, Biosciences), with the firefly luciferase activity normalized to that of Renilla luciferase.

Western Blot

FaDu cells were transfected with LNA-scrambled or LNA-193b, 72 hours post-transfection and lysed in 1 M Tris-HCl (pH 8), 5 M NaCl, and 1% NP40 plus the protease inhibitor cocktail (Roche Diagnostics). Protein concentration was assessed using the Bio-Rad Detergent- Compatible Protein Assay (Bio-Rad Laboratories). A total of 30 mg of protein was loaded onto 4–12% Tris-glycine
protein gels (Invitrogen) for electrophoresis. The protein was transferred onto a PVDF (polyvinylidene fluoride) membrane using a mini Trans-Blot wet Transfer Cell (Bio-Rad). Next, membranes were blocked with Odyssey Blocking Buffer (Li-cor Biosciences). The membranes were probed with anti-NF1 rabbit polyclonal antibody (SC-67, 1/5000 dilution, Santa Cruz), anti-Phospho-Erk rabbit monoclonal antibody (4370, 1/1000 dilution, Cell Signalling Technology), anti-Erk mouse monoclonal antibody (L34F12 1/1000 dilution, Cell Signalling Technology), anti-tubulin mouse monoclonal antibody (1/5000 dilution, Sigma), anti-B-actin mouse monoclonal antibody (1/5000 dilution, Sigma), all followed by IRDye(r) Fluorescent secondary antibodies (1:20,000 dilution; Li-Cor Biosciences). Westerns blots were quantified using Odyssey Application Software 2.1 (Li-Cor Biosciences). When blotting for p-ERK at the 72-hour time point, the media was changed 24 hours after transfection with LNA-193b Biosciences). When blotting for p-ERK at the 72-hour time point, the media was changed 24 hours after transfection with LNA-193b 

Immunoprecipitation

Cells were lysed in 1 M Tris-HCl (pH 8), 5 M NaCl, and 1% NP40 plus the protease inhibitor cocktail (Rochie Diagnostics). Immunoprecipitations were performed with glutathione-Sepharose 4 Fast Flow (GE Healthcare) coupled to GST-RBD (GST-fused to the Ras binding domain) [16] and then combined with lysed LNA Scramble or LNA 193b cells for 2 hours at 4°C. The mixture was then washed four times with lysis buffer containing 220 mM NaCl and eluted. Whole Cell lysates or immunoprecipitates were resolved with PVDF (polyvinylidene fluoride) membrane using a mini Trans-Blot wet Transfer Cell (Bio-Rad), as described above. Proteins were probed using anti-RAS mouse monoclonal antibody (1/1000 dilution, Sigma), anti-NF1 rabbit monoclonal antibody (10C12 1/1000 dilution, Cell Signalling Technology), anti-Erk mouse monoclonal antibody (4370, 1/1000 dilution, Cell Signalling Technology), anti-tubulin mouse monoclonal antibody (L34F12 1/1000 dilution, Cell Signalling Technology), and antibodies against NF1 (Sigma). The membranes were probed with anti-NF1 rabbit polyclonal antibody (SC-67, 1/5000 dilution, Santa Cruz), anti-NF1 rabbit monoclonal antibody (10C12 1/1000 dilution, Cell Signalling Technology), anti-Erk mouse monoclonal antibody (4370, 1/1000 dilution, Cell Signalling Technology), anti-tubulin mouse monoclonal antibody (L34F12 1/1000 dilution, Cell Signalling Technology), anti-B-actin mouse monoclonal antibody (1/5000 dilution, Sigma), all followed by IRDye(r) Fluorescent secondary antibodies (1:20,000 dilution; Li-Cor Biosciences). Westerns blots were quantified using Odyssey Application Software 2.1 (Li-Cor Biosciences). When blotting for p-ERK at the 72-hour time point, the media was changed 24 hours after transfection with LNA-193b and LNA-scrambled since no protein otherwise would be detected.

**In situ Hybridization (ISH) of miR-193b Expression**

Expression of miR-193b was evaluated in HNSCC patient samples using in situ hybridization on 5 um thick FFPE sections. A catalyzed signal amplification system method (GenPoint signal amplification system; DakoCytomation) was performed using 5’ biotin-labelled miR-193b miRCURY™ locked nucleic acid detection probe, or a scrambled negative control probe (50 mmol/L; Exiqon). Positive hybridization signals were visualized by adding the chromogenic substrate diaminobenzidine.

**Immunohistochemistry of P-ERK**

Expression of p-ERK was evaluated on primary HNSCC specimens using microwave antigen retrieval in combination with the Level-2 Ultra Streptavidin System and anti-Phospho-Erk rabbit mAb (4370, 1/600 dilution).

**Statistical Analysis**

All experiments have been performed at least three independent times, and the data are presented as the mean ± SEM. The statistical significance between two treatment groups was determined using the Student’s t test. Analysis and graphs were completed using Graphpad Prism Software (Graphpad Software, Inc).

**Results**

**miR-193b is Over Expressed in Primary HNSCC Tissues and Cell Lines**

Global miRNA expression profiling of 51 primary HNSCC tissues previously conducted in our lab revealed elevated miR-193b expression in relapsed vs. non-relapsed patients (Fig. S1A) [10]. Similarly, over expression of miR-193b was also observed in the FaDu, UTSCC 42a and UTSCC 8 cell lines, compared to the normal oral epithelial (NOE) cell line (Fig. 1).

**In vitro and in vivo Effects of miR-193b Down Regulation**

In order to assess the biological significance of miR-193b over expression, knockdown experiments were conducted in the HNSCC cells using a locked nucleic acid (LNA) approach. Corroborating the sustained reduction in miR-193b expression observed in vivo after LNA-193b was observed for due to 72 hours for all three HNSCC cell lines (Fig. S1B), with the most significant reduction observed in the FaDu cells at 72 hours. Consistent with these results, FaDu cells demonstrated a significant reduction in cell viability and colony formation (by 50%) 72 hours after transfection with LNA-193b compared to LNA-Scramble (Fig. 2A&2B); these results were replicated in the UTSCC 42 and 8 cell lines (Fig. S1C&S1D). Cell cycle analysis was employed to examine the mode of cytotoxicity inflicted by miR-193b knock-down. FaDu cells transfected with LNA-193b displayed a slight increase in the percentage of cells in sub-G1 phase with a corresponding minor reduction in the G0–G1 population (Fig. S1E). The FaDu cells were selected as the primary model for the majority of this study given their superior transfection efficiency, sustained knockdown, and consistent phenotype observed across the MTS, clonogenic and cell cycle assays.

Suppression of miR-193b also led to a significant decrease in migration (30%), and invasion (50%) of FaDu cells compared to negative control (Fig. 2C, 2D). Tumorigenicity was measured in vivo using SCID mice injected intra-muscularly with FaDu cells transfected with LNA-193b or LNA-scrambled. Although not significant, suppression of miR-193b delayed tumour formation compared to the negative control (Fig. 2E), which corroborated the in vitro miR-193b phenotype. To better understand the pathway mediating this phenotype, we sought to identify potential mRNA targets of miR-193b.

![Figure 1. miR-193b is over expressed in HNSCC.](image_url)
miR-193b downregulation reduced cell proliferation, migration and invasion in vitro, and delayed tumor formation in vivo. (A) FaDu cells were transfected with 40 nM of LNA-scramble or LNA-193b. Cell viability was assessed in FaDu cells by the MTS assay 24–72 hours post transfection. (B) Clonogenic survival of FaDu cells was measured 10 to 12 days after re-seeding cells treated with LNA-scramble (40 nM) or LNA-193b (40 nM) for 72 hours. (C) Representative images (right) and quantification (left) depicting the reduced ability of FaDu cells to migrate after transfection with LNA-193b (40 nM) compared to LNA-scrambled (40 nM). (D) Representative images (right) and quantification (left) depicting the reduced ability of FaDu cells to invade after transfection with LNA-193b (40 nM) compared to LNA-scrambled (40 nM). (E) FaDu cells were transfected...
MiR-193b is a Negative Regulator of Tumour Suppressor Genes in HNSCC

To identify potential targets of miR-193b, we used a tri-modal approach previously described by our lab which incorporates in silico prediction algorithms, experimentally-determined data, and publicly available patient data [17]; more details are provided in Fig. S2A. With this approach, 13 overlapping transcripts were identified as potential targets under the control of miR-193b: PRRT3, IGBP5, PER2, SARM1, SLCO1A3, CASP9, FABP4, DAB21P, APC2, TP53INP1, ST3GAL5, DUSP1 and NF1. To validate these candidate targets, mRNA transcript levels were measured by qRT-PCR at 72 hours post-miR-193b knockdown. The results demonstrated that the level of 3 candidate targets (PER2, DUSP1 and NF1) increased significantly by >1.5-fold after miR-193b knockdown, compared to the negative control (Fig. 3A). Next, the basal mRNA expression level of PER2, DUSP1 and NF1 was evaluated in the HNSCC cell lines (FaDu, UTSCC42a and UTSCC8) compared to the NOE cells, demonstrating that PER2 and NF1 were indeed significantly lower in these cell lines (<0.75 fold), thus were selected for further validation (Fig. 3B). After miR-193b knockdown, both NF1 and PER2 transcript (Fig. 3C, and Fig. S2B, S3A–S3B) and protein expression levels (Fig. 3D and Fig. S3C) increased significantly compared to the negative control. These findings indicated that both NF1 and PER2 were highly probable targets of miR-193b in HNSCC cells.

MiR-193b Directly Targets NF1 in HNSCC Cell Lines

To establish a direct interaction between miR-193b and the 3′UTR of NF1, a luciferase assay was employed. FaDu cells co-transfected with pMIR-REPORT-NF1 and LNA-193b demonstrated a significant increase in luciferase activity (~1.5-fold) compared to control cells (Fig. 3E). This effect was completely abrogated after mutating the 3′UTR of miR-193b, thereby validating NF1 as a bona fide miR-193b target (Fig. 3E). Similarly, a luciferase construct was designed for PER2 but demonstrated a decrease in p-ERK expression compared to the negative control (Fig. 3F). To examine if the interaction between miR-193b and NF1 propagated down the RAS signalling pathway, we evaluated p-ERK expression, a kinase located downstream of RAS. Knockdown of miR-193b in FaDu cells indeed led to a decrease in p-ERK expression compared to the negative control (Fig. 4A). Given the involvement of p-ERK in promoting cell proliferation and migration, we treated FaDu cell with a MEK/ERK kinase 1/2 pharmacologic inhibitor (U1026) which blocks p-ERK activity [19]. FaDu cells treated with U1026 demonstrated a reduction in cell viability compared to the negative control (DMSO) (Fig. 4B). Furthermore, FaDu cells treated with U0126 illustrated a significant reduction in migration (50%) and invasion (45%) compared to cells treated with DMSO (Figs. 4C&D). These results recapitulated the phenotype observed after miR-193b knockdown, suggesting that this pathway might indeed be mediating the effects of the miR-193b–NF1 axis.

MiR-193b Over Expression is Associated with Poor Survival and Increased p-ERK Expression in Primary HNSCC

In situ hybridization was utilized to visually confirm miR-193b expression in primary HNSCC tissues. A miR-193b signal was observed in the cytoplasm of the tumour cells (Fig. 5A), but not in the adjacent infiltrating lymphocytes, or when using the scrambled control probe (Figs. S4A–B). Another negative control was provided by a primary human breast cancer tissue wherein no miR-193b signal was observed (Fig. S4C). In the same HNSCC biopsy tissue, intense immuno-expression of p-ERK was also observed in the nucleus and cytoplasm of the tumour cells, but not in the adjacent stroma or infiltrating lymphocytes (Fig. 5B, and Fig. S4D). These findings support an association between miR-193b with p-ERK co-expression. Finally, when the expression of miR-193b from the 51 HNSCC patients previous profiled by our lab [10] was dichotomized between high miR-193b (> median) vs. low (≤ median) expression, the former group experienced a worse disease-free survival compared to the latter (HR = 1.41; p = 0.18); although statistical significance was not attained due to the small cohort size (Fig. 5C).

Discussion

A global miRNA profiling study previously conducted in our lab [10] identified the over expression of miR-193b as a dysregulated miRNA in HNSCC patients. Herein, we report for the first time that miR-193b can target NF1, which in turn leads to ERK activation, as one pathway to promote HNSCC progression. Our study demonstrated that the down regulation of miR-193b decreased cell viability, clonogenicity, migration, invasion, and tumour formation, which in turn, was associated with increased NF1 and a decrease in ERK phosphorylation. Furthermore, HNSCCs with higher miR-193b expression levels fared worse than lower miR-193b tumours, which all collectively demonstrate that dysregulation of the miR-193b–NF1–ERK axis is yet another mechanism which can drive HNSCC progression. Over expression of miR-193b has been described previously in HNSCC [11], uveal melanomas [20] and multiple myeloma [21]. The precise mechanism for miR-193b over-expression remains unclear; it is located on chromosome 16p11.13, a region not previously described to be amplified in HNSCC. Alterations in key players of the miRNA processing machinery, such as Dicer, Drosha, DGRCR8, AGO2 or XPO5, have been reported to contribute to aberrant miRNA expression [22]. For instance, elevated global miRNA expression in salivary gland pleomorphic adenomas have been associated with elevated expression of Dicer, Drosha or DGRCR8 expression [23]. In addition, oncocogenic proteins such as MYC have been described to bind to the locus of miRNAs such as miR-9, activating their transcription [24]. Hence, it is certainly possible that several different mechanisms can account for elevated miR-193b expression in HNSCC, although the precise process remains to be elucidated.
Figure 3. Identification of mRNA targets of miR-193b. (A) qRT-PCR of 13 predicted miR-193b targets, 72 hours post transfection with LNA-193b (40 nM), fold change relative to LNA-scramble (40 nM). (B) Basal mRNA expression of PER2, DUSP1 and NF1 was assessed using qRT-PCR in all three HNSCC cell lines relative to NOE cells. (C) NF1 transcript expression in FaDu cells was measured 72 hours post transfection with LNA-193b (40 nM) or LNA-scramble (40 nM). (D) Western blotting of NF1 in FaDu cells was determined 72 hours post transfection, images (above), quantification (below). (E) Relative luciferase activity of FaDu cells after co-transfection with pMIR-NF1 UTR (100 ng) or pMIR-NF1 Mutant (100 ng) vectors, and LNA-193b (40 nM) or LNA-scramble (40 nM), 72 hours post transfection. (F) Immunoprecipitation of GST-RBD in FaDu cells post transfection with LNA 193b (40 nM) or LNA Scramble (40 nM); images (above), quantification (below). *P<0.05, **P<0.005, ***P<0.0005, P = ns (not significant).
doi:10.1371/journal.pone.0053765.g003
The role of miR-193b in human malignancies appears to be controversial. In our study, miR-193b appears to be mediating oncogenic signals; other reports in breast, prostate and leukemia, however, have identified miR-193b to be a tumour suppressor, wherein low miR-193b expression promoted tumour progression [25,26,27]. The opposing effects of the same miRNA in different

Figure 4. P-Erk expression contributes to cell viability, migration and invasion. Western blotting of p-ERK was measured in FaDu cells 72 hours post transfection with LNA-193b (40 nM) or LNA-scrambled (40 nM); images (above), quantification (below). (B) Cell viability of FaDu cells was assessed by the MTS assay 24, 48 and 72 hours after treatment with U0126 (10 uM) or vehicle control DMSO (10 uM). (C) Representative images (right) and quantification (left) depicting the reduced ability of FaDu cells to migrate after treatment with U0126 (10 uM) or vehicle control DMSO (10 uM). (D) Representative images (right) and quantification (left) depicting the reduced ability of FaDu cells to invade after treatment with U0126 (10 uM) or vehicle control DMSO (10 uM). *P<0.05, **P<0.005, P=ns (not significant).

doi:10.1371/journal.pone.0053765.g004
malignancies have been previously reported. As an example, miR-205, which was observed to be over expressed in HNSCC [10,28,29], endometrial [30] and lung [31] cancers, was in fact under-expressed in breast cancers [32]. Similarly, global miRNA profiliings of six human solid malignancies demonstrated tissue specific expression of miRNAs [33], further corroborating the complex expression patterns and biology of miRNAs.

In this current study, we identified NF1 as one target for miR-193b. NF1 is a RAS-GTPase (see Fig. 6), which accelerates the conversion of active RAS-GTP into inactive RAS-GDP, thereby negatively regulating RAS signalling [34]. RAS bound to GTP activates Raf which triggers a cascade of mitogen activated protein kinases (MAPKs). Signals emanating from this cascade can regulate genes involved in cell growth, death, differentiation and migration [18], demonstrating the central role for this pathway in promoting tumour progression. In glioblastoma, NF1 inactivating mutations were identified from a large panel of sequenced tumors, suggesting NF1's relevance to the development of sporadic glioblastoma [35,36]. Furthermore, mutations and genomic alterations of NF1 have been reported in a number of other cancer cells and tumor tissues [37,38,39]. In vitro, the importance of NF1 was demonstrated in NIH 3T3 cells, which when over expressed, displayed a reduction in cell growth compared to untreated cells [40], further supporting a tumor suppressor role for NF1 via RAS inhibition. ERK is a MAPK kinase located downstream of Raf and MEK in the RAS signalling pathway. We observed an inverse relationship between NF1 and ERK activation, whereby suppression of miR-193b led to an increase in NF1 and decreased p-ERK. These findings illustrate the ability of the miR-193b, NF1 interaction to propagate downstream of RAS signalling. Since activated p-ERK can translocate into the nucleus and bind to the promoter of genes which promote cell growth, death and migration [18,41], it follows that the observed miR-193b phenotype might be attributable to ERK activation. This was corroborated by pharmacologic inhibition of p-ERK (with U0126), which recapitulated the same phenotype as observed with miR-193b knockdown. Moreover, HNSCC patients with high miR-193b expression also expressed high levels of p-ERK, providing a translational corroboration between miR-193b and p-ERK. The relevance of the ERK pathway in HNSCC has also been reported by others, wherein treatment of HNSCC cells (UM-SCC-9 and UM-SCC-11B) with U0126 decreased cell viability [42], confirming the observations made in this current study.

Given the negative regulatory role of NF1 on RAS activation, it is conceivable that tumours which over-express miR-193b, thereby
down regulating NF1, could constitutively activate the RAS signalling pathway. Colorectal cancer patients with activating RAS mutations are resistant to EGFR inhibitors such as Cetuximab [43,44]. The landmark trial of Cetuximab combined with radiation therapy [45] has transformed clinical management of HNSCC; however, not every patient responds to this regimen, suggesting alternate pathways by which HNSCCs can escape EGFR inhibition [46]. One speculation that could arise from our data might be the possibility that the miR-193b–NF1 axis might account for Cetuximab resistance. Thus, it would be of interest to assay miR-193b expression in relation to Cetuximab sensitivity in HNSCC patients.

PER2 was the second potential miR-193b target identified in this study; PER2 is a tumour suppressor involved in regulation of the circadian rhythm, which in turn controls cellular processes such as proliferation, apoptosis, metabolism and DNA repair [47]. In this current study, we established an interaction between miR-193b and PER2, whereby miR-193b knockdown increased PER2 transcript and protein expression (Fig. S3). PER2 under-expression was recently reported for 40 HNSCC primary patient tumour samples [48]; furthermore, leukemic cells over expressing PER2 also led to a reduction in proliferation and clonogenicity [49], which corroborates our miR-193b phenotype (Fig. 2). Finally, PER2 has also been described to be a negative regulator of c-myc [50], a potent oncogene involved in proliferation, differentiation, migration, and invasion [51]. Hence, in this current report, we propose a miRNA-mediated mechanism for PER2 under-expression, which in turn, promotes HNSCC progression.

The translational impact of this study have been demonstrated by the potential prognostic value of miR-193b over expression in

Figure 6. Proposed model for the role of miR-193b in regulating HNSCC cell proliferation and migration. Schema showing over expression of miR-193b leads to the down regulation of NF1, which prevents RAS-GTP from hydrolyzing into inactive RAS-GDP. This in turn triggers RAS signalling which leads to activation of a cascade of mitogen activated protein kinases (MAPKs), including p-ERK which can then translocate into the nucleus and promotes the expression of genes involved in cell proliferation and migration, driving HNSCC progression. Boxes indicate data demonstrated in this study.

doi:10.1371/journal.pone.0053765.g006
its association with worse outcome (Fig. 5C), in turn associated with P-ERK expression (Fig. 5B). Micro-RNAs themselves cannot yet readily serve as therapeutic targets; however, it is conceivable that the ERK pathway could be potentially inhibited. Pre-clinical studies have certainly demonstrated the growth inhibitory effects of p-ERK inactivation in HNSCC cells [42], along with reduced migration and invasion. There are medicinal chemistry approaches currently being explored for more specific ERK inhibitors [52,53,54]; our present study would certainly suggest this could indeed be a fruitful pursuit in an effort to further improve outcome for HNSCC patients, particularly those who might be resistant to Cetuximab combined with RT.

In summary, we have identified a novel oncogenic role for miR-193b, whereby high miR-193b suppresses NF1, in turn activating p-ERK, leading to increased HNSCC cell proliferation, invasion, migration, and tumour formation (Fig. 6). These findings suggest yet another mechanism which could account for the aggressive behaviour of this disease. The translational impact of this study lie in the potential prognostic value of miR-193b, along with P-ERK serving as a possible therapeutic target by which outcome for HNSCC patients could be further improved.

Supporting Information

Figure S1 miR-193b over expression in HNSCC induced cell proliferation in UTSCC 42a and UTSCC 8 cells. (A) qRT-PCR analysis for miR-193b was conducted on 51 HNSCC primary tissue samples showing high expression in 43 relapsed vs. low expression for 8 non-relapsed tumors, relative to the expression of four normal larynx tissues. (B) qRT-PCR of miR-193b expression in HNSCC cell lines 24–72 hours after transfection with LNA-193b (40 nM) or LNA-scramble (40 nM). (C) Cell viability was assessed in UTSCC 42a and 8 cells by the MTS assay 24, 48 and 72 hours post transfection with LNA-193b (40 nM) or LNA-scramble (40 nM). (D) Clonogenic survival of UTSCC 42a and 8 cells was measured 72 hours post transfection with LNA-193b (40 nM) or LNA-scramble (40 nM). *P < 0.05, **P < 0.005, P = ns (not significant).

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
2. Ferlay J, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.
3. Leemans CR, Braakhuis BJ, Beekhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9–22.
4. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
5. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857–866.
6. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136: 506–591.
7. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704–714.
8. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635–647.
9. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793–1801.
10. Hui AB, Lenarduzzi M, Krushel T, Waldrum L, Puntille M, et al. (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16: 1129–1139.
11. Avisar M, Christensen BC, Kelsey KT, Marsit CJ (2009) MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 15: 2850–2855.
12. Crippings B, Keane T, Puntille M, Warde P, Waldrum J, et al. (2007) Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 85: 7–16.
13. Pekola-Heino K, Kulmala J, Grenman R (1992) Sublethal damage repair in squamous cell carcinoma cell lines. Head Neck 14: 196–199.
14. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, et al. (2007) Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 29: 163–188.
15. Hui AB, Yue S, Shi W, Alajez NM, Ito E, Hui AB, Shi W, et al. (2011) MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 71: 2381–2391.
16. Le LP, Parada LF (2007) Tumor microenvironment and neurofibromatosis type 1 connect the Gaps. Oncogene 26: 4609–4616.
17. Moniz LS, Stambolic V (2011) Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response to UV irradiation. Mol Cell Biol 31: 30–42.
18. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, et al. (2007) Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 29: 163–188.
19. Nakamura T, Gulick J, Pratt R, Robbins J (2009) Noonan syndrome is craniofacial malformations. Proc Natl Acad Sci U S A 106: 15436–15441.
20. Worley IA, Long MD, Ohken MD, Harbour JW (2008) Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res 18: 184–190.

21. Unno K, Zhou Y, Zimmerman T, Platania LG, Wickrema A (2009) Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma. Leuk Lymphoma 50: 1865–1871.

22. van Kooswinkel M, Keede M, Agami R (2011) MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11: 644–654.

23. Zhang X, Cairns M, Rose B, O’Brien C, Shannon K, et al. (2009) Alterations in miRNA processing and expression in prolemorphic adenomas of the salivary gland. Int J Cancer 124: 2053–2063.

24. Ma L, Young J, Prabhala H, Fan E, Mendaghi P, et al. (2010) miR-9, a MYC/ MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247–256.

25. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, et al. (2010) miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127: 1363–1372.

26. Li XF, Yan PJ, Shao ZM (2009) Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 28: 3937–3946.

27. Gao XN, Lin J, Guo L, Li YH, Wang LL, et al. (2011) MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res 35: 1226–1232.

28. Fletcher AM, Hoadford AC, Trask DK (2000) Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific miR-205. Transl Oncol 1: 202–208.

29. Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, et al. (2007) MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 358: 12–17.

30. Wu W, Lin Z, Zhuang Z, Liang X (2009) Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 18: 50–55.

31. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, et al. (2006) A microRNA expression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696–1704.

32. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612–11620.

33. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257–2262.

34. Martin GA, Viscochi D, Bollag G, McCabe PC, Crossog JW, et al. (1990) The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63: 843–849.

35. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma multiforme. Science 321: 1070–1072.

36. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1070–1072.

37. Li Y, Bollag G, Clark R, Stevens J, Conroy L, et al. (1992) Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 69: 275–281.

38. The I, Murthy AE, Hannigan GE, Jacoby LB, Menon AG, et al. (1993) Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet 3: 62–66.

39. Thiel G, Marczinek K, Neumann R, Wiuckowski R, Marchuk DA, et al. (1995) Somatic mutations in the neurofibromatosis 1 gene in glomas and primitive neuroectodermal tumours. Anticancer Res 15: 2495–2499.

40. Johnson MR, DeClercq JE, Felzmann S, Vass WG, Xu G, et al. (1994) Neurofibromin can inhibit Ras-dependent growth by a mechanism independent of its GTPase-accelerating function. Mol Cell Biol 14: 641–645.

41. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, et al. (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192–222.

42. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, et al. (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal pathways on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538–548.

43. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643–2648.

44. Lecure A, Bachet JB, Boige V, Gaye A, Le Corre D, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374–379.

45. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21–28.

46. Cassell A, Grandis JR (2010) Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs 19: 709–722.

47. Wood PA, Yang X, Hrushowsky WJ (2009) Clock genes and cancer. Integr Cancer Ther 8: 303–308.

48. Hsu CM, Lin SF, Lu CT, Lin PM, Yang MY (2011) Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol 33: 149–155.

49. Grey S, Gombart AF, Yi WS, Koeller C, Hofmann WK, et al. (2005) Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106: 2827–2836.

50. Fu L, Peliciano H, Liu J, Huang P, Lee C (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111: 41–50.

51. Woller A, Ramaswamy S (2011) MYC and metastasis. Cancer Res 71: 2034–2037.

52. Boston SR, Deshmukh R, Strome S, Priyakumar UD, MacKerril AD, Jr, et al. (2011) Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9. BMC Cancer 11: 7.

53. Ohori M, Kinoshita T, Okubo M, Sato K, Yamaaaki A, et al. (2005) Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 336: 357–363.

54. Hancock CN, Macias A, Lee EK, Yu SY, Mackrell AD Jr, et al. (2005) Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J Med Chem 48: 4586–4595.